Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Histopathological classifications of neuroendocrine neoplasms (NEN) change regularly and the latest WHO classification published in 2022, which concerns all NEN in the body, attempts to standardize classifications in the different locations. Differentiation and proliferation mainly assessed by Ki-67 index are still the cornerstone of those classifications. However, many markers are now used for diagnostic (to check neuroendocrine differentiation, to identify the site of origin of a metastasis, to help separating high-grade neuroendocrine tumors/NET and neuroendocrine carcinoma/NEC), prognostic or theranostic purposes. NENs are often heterogeneous and this can lead to difficulties in classifications, biomarker and prognostic assessment. These different points are discussed successively in this review, insisting especially on the frequent digestive, gastro-entero-pancreatic (GEP) localizations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beem.2023.101795 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MiNEN, amphicrine carcinomas, and conventional carcinomas with neuroendocrine differentiation: diagnostic criteria, open questions, and future perspectives.
Virchows Arch
September 2025
Institute of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany.
Mixed neuroendocrine and non-neuroendocrine neoplasms (MiNEN) represent a heterogeneous group of bidirectionally differentiated epithelial malignancies that are, in most cases, highly aggressive. They are defined by the presence of morphologically distinct, yet clonally related, neuroendocrine and non-neuroendocrine components, each comprising at least 30% of the tumor mass according to current guidelines. Tumors that fall within the differential diagnostic spectrum of MiNEN include amphicrine carcinomas-characterized by the co-expression of neuroendocrine and non-neuroendocrine features within the same tumor cell-as well as conventional carcinomas that lack neuroendocrine morphology but exhibit immunohistochemical expression of neuroendocrine markers.
View Article and Find Full Text PDFGastroenteropancreatic neuroendocrine tumors: A retrospective study conducted in the Colombian Southwest.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Departamento de Medicina Interna, Servicio de Gastroenterología, Fundación Valle del Lili, Cali, Colombia. Electronic address:
Introduction And Aim: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms originating in neuroendocrine cells from the gastric mucosa and submucosa, small intestine, large intestine, rectum, and pancreas. Our aim was to describe their histopathologic, endoscopic, and clinical characteristics and the experience with these tumors at a tertiary care hospital center in the Colombian Southwest.
Materials And Methods: A retrospective, analytic, observational, and descriptive study included 93 patients diagnosed with GEP-NETs, within the time frame of 2018 and 2022.
Reprogramming the immunologically cold landscape of prostate cancer through MAOA inhibition.
J Immunother Cancer
September 2025
Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA
Prostate cancer (PC) is notoriously known for exhibiting an immunologically cold phenotype in the tumor immune microenvironment (TIME), leading to the need for interventions to enhance immunotherapy efficacy. Recent findings by Zhao in the identified stromal monoamine oxidase A (MAOA), a key enzyme that degrades monoamine neurotransmitters and plays a role in the neuroendocrine system, as a critical regulator of the immune response to PC. Altering MAOA levels in myofibroblastic cancer-associated fibroblasts, either genetically or pharmacologically, can reprogram PC's TIME to modulate CD8 T cell-mediated cytotoxicity through the WNT5A-Ca²-NFATC1 signaling axis, highlighting the stromal influences on CD8 T cell cytotoxic activity within the TIME.
View Article and Find Full Text PDFA National Cancer Database analysis of the clinicopathologic characteristics and outcomes of appendiceal neuroendocrine tumors.
Surgery
September 2025
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL. Electronic address:
Introduction: Appendiceal neuroendocrine neoplasms are rare lesions which are generally incidentally discovered during or after appendectomies. Recent advances have refined their classification and improved diagnostic rates, highlighting their distinct pathologic and clinical presentations. The present study aimed to assess the characteristics and outcomes of appendiceal neuroendocrine neoplasms using data from the U.
View Article and Find Full Text PDFCase Report: Ectopic CRH production by adrenal adenoma as a unique cause of the ACTH-dependent Cushing's syndrome.
Front Endocrinol (Lausanne)
September 2025
Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
Isolated ectopic secretion of corticotropin-releasing hormone (CRH) is an exceedingly rare cause of Cushing's syndrome (CS), accounting for fewer than 1% of cases. Ectopic CS is an uncommon but potentially life-threatening condition that often necessitates urgent diagnostic evaluation and treatment. Hormonal testing may suggest a pituitary origin, complicating the diagnostic process.
View Article and Find Full Text PDF